Tumor-targeting oncolytic viruses engineered for glioblastoma immunotherapy
We report the development of an oncolytic virus engineered for enhanced targeting of tumor cells, increased safety, and greater antitumor efficacy through the expression of multiple transgenes that remodel the immunosuppressive GBM tumor microenvironment Overall design: GBM-bearing mice (C57BL/6) were treated with an engineered oncolytic virus or a control virus at day 7 post tumor implantation. At day 20, mice were sacrificed for analysis.